Ionis Pharmaceuticals, Inc. Forecast, price target & analysts
Ionis Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Ionis Pharmaceuticals, Inc. Classifications & Recommendation:
Ionis Pharmaceuticals, Inc. Price Target
| Target Price | $79.56 |
| Price | $71.55 |
| Potential |
11.20%
register free of charge
|
| Number of Estimates | 26 |
|
26 Analysts have issued a price target Ionis Pharmaceuticals, Inc. 2026 .
The average Ionis Pharmaceuticals, Inc. target price is $79.56.
This is
11.20%
register free of charge
$100.80
40.88%
register free of charge
$46.46
35.07%
register free of charge
|
|
| A rating was issued by 31 analysts: 24 Analysts recommend Ionis Pharmaceuticals, Inc. to buy, 7 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ionis Pharmaceuticals, Inc. stock has an average upside potential 2026 of
11.20%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 705.14 | 902.28 |
| 10.48% | 27.96% | |
| EBITDA Margin | -65.68% | -41.33% |
| 61.22% | 37.07% | |
| Net Margin | -64.37% | -42.13% |
| 38.42% | 34.55% |
28 Analysts have issued a sales forecast Ionis Pharmaceuticals, Inc. 2025 . The average Ionis Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
12 Analysts have issued an Ionis Pharmaceuticals, Inc. EBITDA forecast 2025. The average Ionis Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
28 Ionis Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Ionis Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.04 | -2.36 |
| 18.75% | 22.37% | |
| P/E | negative | |
| EV/Sales | 11.72 |
28 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast for earnings per share. The average Ionis Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Ionis Pharmaceuticals, Inc....
Current Ionis Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 10 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 04 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 30 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Oct 30 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Oct 30 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Oct 30 2025 |
| Raymond James |
Locked
➜
Locked
|
Locked | Oct 30 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 10 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 04 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 30 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Oct 30 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Oct 30 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Oct 30 2025 |
|
Locked
Raymond James:
Locked
➜
Locked
|
Oct 30 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
